Q2 FY2026 EarningsQ2 FY26 performance significantly beat consensus estimates across all major financial metrics, primarily driven by a $27.8M licensing revenue recognition from the Amoytop partnership. Revenue reached $27.8M vs. $13.2M expected (+110.73%), while Diluted EPS (GAAP) of -$0.14 substantially outperformed the -$1.18 mean estimate. Strategic progress in the HBV pipeline, including the $25M upfront payment for pevifoscorvir sodium and IND approval for ALG-170675, has significantly bolstered the company's non-dilutive capital and clinical outlook.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Aligos Therapeutics(ALGS) the Revenue is 27.78 M (+2779%), Beat estimate;the EBIT is -1.89 M (+89.82%), Beat estimate;the EPS is -0.14 (+90.85%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B2778.55%
0.01B1420.10%
+0.01B1,358.45%
EBITExceed expectations
-0.00B89.82%
-0.02B15.34%
+0.01B74.48%
EPSExceed expectations
-0.1490.85%
-1.093528.53%
+0.953562.32%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf